

TABLE 209: EPOETIN USE/BLOOD TRANSFUSION

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	EPOETIN USE			BLOOD TRANSFUSION		
			n	N	%	n	N	%
Bacon et al., 2011 RESPOND2	1	(1) PR48	17	80	21%	0	80	0%
		(74) B32 PR36-48 RGT	66	162	41%	3	162	2%
Bourlière et al., 2015 SIRIUS	1	(7) SOF24 + LDV24	0	77	0%	0	77	0%
		(10) SOF12 + LDV12 + RBV12	0	78	0%	1	78	1%
Lawitz et al., 2014 LONESTAR	1	(6) SOF12 + LDV12	0	19	0%	NR		
		(10) SOF12 + LDV12 + RBV12	0	21	0%			
Reddy et al., 2015 ATTAIN	1	(39) T12 PR48 q8	25	384	7%	35	384	9%
		(68) SIM12 PR48	14	379	4%	3	379	1%
Zeuzem et al., 2014 SAPPHIRE-II	1	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	0	297	0%	0	297	0%

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; b.i.d. = twice daily; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; NR = not reported; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q.d. = once daily; RBV = ribavirin; RGT = response-guided therapy; RIT = ritonavir; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.